Related Experiment Video
Updated: Jul 24, 2025
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
[Efficacy and safety of convalescent plasma administration in patients with COVID-19 infection]
Priscila Edith Escobedo-Sánchez1, Ibis de la Cruz-Hernández2, Meztli Ramos-García1
1División Académica de Ciencias de la Salud (DACS), Universidad Juárez Autónoma de Tabasco (UJAT), Villahermosa, Tabasco, México.
Introduction:
During the COVID-19 pandemic, several strategies were suggested for the management of the disease, including pharmacological and non-pharmacological treatments such as convalescent plasma (CP). The use of CP was suggested due to the beneficial results shown in treating other viral diseases.
Objective:
To determine the efficacy and safety of CP obtained from whole blood in patients with COVID-19.
Methods:
Pilot clinical trial in patients with COVID-19 from a general hospital. The subjects were separated into three groups that received the transfusion of 400ml of CP (n=23) or 400ml of standard plasma (SP) (n=19) and a non-transfused group (NT) (n=37). Patients also received the standard available medical treatment for COVID-19. Subjects were followed up daily from admission to day 21.
Results:
The CP did not improve the survival curve in moderate and severe variants of COVID-19, nor did it reduce the degree of severity of the disease evaluated with the COVID-19 WHO and SOFA clinical progression scale. No patient had a severe post-transfusion reaction to CP.
Conclusions:
Treatment with CP does not reduce the mortality of patients even when its administration has a high degree of safety.
